Aripiprazole is a second-generation antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A receptors, which may help modulate neural hyperactivity associated with Visual Snow Syndrome. By partially stimulating dopamine receptors and stabilizing neurotransmitter signaling, it potentially reduces aberrant cortical and thalamic processing that contributes to the syndrome's visual disturbances.